BioTissue
PrivateLast Round
Series C
Jun 26, 2019
Total Funding Raised
$117.25M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
BioTissue operates in Healthcare & Life Sciences and is based in Miami, Florida. Its latest recorded funding round was a Series C round in June 2019.
BioTissue is a biotechnology company that develops and commercializes regenerative medicine products derived from human amniotic membrane and umbilical cord tissues for ocular, surgical, and wound care applications.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
BioTissue Comparables
Compare BioTissue with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Merakris Therapeutics | 85% | |
| NuVision Biotherapies | 83% | |
| Surgenex | 83% |
For institutional investors. Book with your work email.
BioTissue Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jun 26, 2019 | ||||
| Series B | Jun 23, 2015 | ||||
| Debt | May 12, 2015 | ||||
| Growth Equity | Aug 22, 2013 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
BioTissue Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EW Healthcare Partners | Series C |
| Square 1 Bank | Debt |
| Ballast Point Ventures | Growth Equity, Series C, Series B |
| RC Capital | Growth Equity, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 19, 2026
Monthly visitors increased 46% MoM.
- Jan 23, 2026
Acquiring surgical and wound care business for up to $40 million.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- recognized_asOct 16, 2026
BioTissue, Inc. is named to the 2026 Fortune Best Workplaces in BioPharma list, presented by Great Place to Work(R) and Fortune magazine, for the third consecutive year, ranking No. 21 based on employee feedback in Florida on Oct 15th '26'.
- recognized_asOct 16, 2026
On Oct 16th '26 in Florida, BioTissue, Inc. ranks #21 on the Fortune Best Workplaces in BioPharma list, presented by Great Place to Work and Fortune for the company’s third consecutive year, based on employee feedback.
- attends_eventOct 9, 2026
BioTissue, Inc. presents results from a Phase 2 study of TTAX03 in adults with mild to moderate dry eye disease at the American Academy of Ophthalmology Annual Meeting in Louisiana on Oct 9th '26.
- hiresOct 6, 2026
On Oct 5th '26 in Florida, BioTissue, Inc. appoints Rocco Venezia, CPA, as Chief Financial Officer, succeeding retiring CFO Mike Cornelius.
- hiresAug 24, 2026
BioTissue, Inc. appoints ophthalmic industry veteran Chris Calcaterra to its board as an independent director, effective immediately, to support its focus on ocular health and ocular surface disease in Florida on Aug 26th '26.
For institutional investors. Book with your work email.
BioTissue Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about BioTissue's valuation, stock price, and market status.
Is BioTissue a public or private company?
BioTissue is a private company.
What is the current stock price of BioTissue?
BioTissue is a private company, so its shares have no public market price. Caplight tracks BioTissue's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is BioTissue worth (valuation)?
Valuation information for BioTissue is not publicly available.
Can I buy BioTissue stock?
BioTissue shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was BioTissue's last funding round?
BioTissue's most recent funding round was Series C on June 26, 2019.
Who are the main investors in BioTissue?
Key investors in BioTissue include EW Healthcare Partners, Ballast Point Ventures, RC Capital.
Will BioTissue IPO soon?
No public IPO plans have been announced for BioTissue.
How can I track BioTissue secondary market activity?
Caplight tracks bids, offers, and trades in BioTissue's shares on secondary markets.